Affordable Inhalers and Nebulizers Act of 2025
Summary
What This Bill Does
The bill requires omnibus provision amending the Public Health Service Act, Internal Revenue Code, and ERISA to mandate coverage of specified inhaler products with cost-sharing capped at $15 per 30-day supply and deductible, requires new PHSA Section 2799A-11 requiring group health plans and individual/group health insurance issuers to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, and requires new IRC Section 9826 requiring group health plans to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, mirroring the PHSA provision for plans regulated. It relies on price controls, compliance mandates, appropriations, and grants. The main policy areas are Healthcare, Finance, and Trade.
Who Benefits and How
Uninsured asthma and COPD patients would be affected, Asthma and COPD patients with private insurance could see lower costs, and Asthma and COPD patients with individual market insurance could see lower costs.
Who Bears the Burden and How
Health insurance issuers (individual and group market) could face higher costs, Health insurance issuers could face higher costs, and Federal government (HHS) could face higher costs.
Key Provisions
- Requires omnibus provision amending the Public Health Service Act, Internal Revenue Code, and ERISA to mandate coverage of specified inhaler products with cost-sharing capped at $15 per 30-day supply and deductible...
- Requires new PHSA Section 2799A-11 requiring group health plans and individual/group health insurance issuers to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply...
- Requires new IRC Section 9826 requiring group health plans to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, mirroring the PHSA provision for plans regulated...
- Requires new ERISA Section 726 requiring group health plans to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, mirroring the PHSA provision for plans regulated...
- Creates new PHSA Section 399V-8 establishing a federal Specified Inhaler Product Payment Program beginning January 1, 2026, under which program-registered providers furnish inhalers to uninsured individuals at no more...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires omnibus provision amending the Public Health Service Act, Internal Revenue Code, and ERISA to mandate coverage of specified inhaler products with cost-sharing capped at $15 per 30-day supply and deductible, requires new PHSA Section 2799A-11 requiring group health plans and individual/group health insurance issuers to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, and requires new IRC Section 9826 requiring group health plans to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, mirroring the PHSA provision for plans regulated.
Key Policy Areas
Healthcare, Finance, Trade
Primary Purpose
The bill requires omnibus provision amending the Public Health Service Act, Internal Revenue Code, and ERISA to mandate coverage of specified inhaler products with cost-sharing capped at $15 per 30-day supply and deductible, requires new PHSA Section 2799A-11 requiring group health plans and individual/group health insurance issuers to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, and requires new IRC Section 9826 requiring group health plans to cover all specified inhaler products with no deductible and cost-sharing capped at $15 per 30-day supply, mirroring the PHSA provision for plans regulated.
Policy Domains
Whole bill
Identified Gains
- Uninsured asthma and COPD patients
- Asthma and COPD patients with private insurance
- Asthma and COPD patients with individual market insurance
- Asthma and COPD patients with group insurance
- Asthma and COPD patients in employer group health plans
Identified Costs
- Health insurance issuers (individual and group market)
- Health insurance issuers
- Federal government (HHS)
- Employer-sponsored group health plans (IRC-regulated)
- ERISA-regulated employer group health plans
Sponsors
Legislative Progress
In CommitteeMs. Alsobrooks (for herself and Mr. Van Hollen) introduced the …
Read twice and referred to the Committee on Finance.
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Asthma and COPD patients in ERISA-regulated group plans, Asthma and COPD patients with group insurance, Asthma and COPD patients with individual market insurance
ERISA-regulated employer group health plans, Employer-sponsored group health plans, Employer-sponsored group health plans (IRC-regulated)
Pharmaceutical inhaler manufacturers
Pharmaceutical inhaler manufacturers faces effects in multiple directions
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology